6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Fluid	NNP	fluid	fluid	fluid	N	B-AdverseReaction
Retention	NNP	retention	retention	retent	N	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
Mineralocorticoid	NNP	mineralocorticoid	mineralocorticoid	mineralocorticoid	N	B-AdverseReaction
Excess	NNP	excess	excess	excess	N	I-AdverseReaction
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Adrenocortical	JJ	adrenocortical	adrenocortical	adrenocort	N	B-AdverseReaction
Insufficiency	NNP	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Hepatotoxicity	NNP	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
fatigue	JJ	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
joint	JJ	joint	joint	joint	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
or	CC	or	or	or	N	O
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hot	JJ	hot	hot	hot	N	B-AdverseReaction
flush	NN	flush	flush	flush	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
and	CC	and	and	and	N	O
contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
anemia	JJ	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
alkaline	NN	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
,	,	,	,	,	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypercholesterolemia	NN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
and	CC	and	and	and	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Janssen	NNP	janssen	janssen	janssen	N	O
Biotech	NNP	biotech	biotech	biotech	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
526	CD	526	526	526	N	O
-	:	-	-	-	N	O
7736	CD	7736	7736	7736	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
JANSSEN	NN	janssen	janssen	janssen	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
randomized	JJ	randomized	randomized	random	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
multicenter	RBR	multicenter	multicenter	multicent	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
castration	NN	castration	castration	castrat	N	O
-	:	-	-	-	N	O
resistant	JJ	resistant	resistant	resist	N	O
prostate	NN	prostate	prostate	prostat	N	O
cancer	NN	cancer	cancer	cancer	Y	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
using	VBG	using	using	use	N	O
a	DT	a	a	a	N	O
gonadotropin	NN	gonadotropin	gonadotropin	gonadotropin	N	O
-	:	-	-	-	N	O
releasing	VBG	releasing	releasing	releas	N	O
hormone	NN	hormone	hormone	hormon	N	O
(	(	(	(	(	N	O
GnRH	NNP	gnrh	gnrh	gnrh	N	O
)	)	)	)	)	N	O
agonist	NN	agonist	agonist	agonist	N	O
or	CC	or	or	or	N	O
were	VBD	were	were	were	N	O
previously	RB	previously	previously	previous	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
orchiectomy	NN	orchiectomy	orchiectomy	orchiectomi	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
both	DT	both	both	both	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
000	CD	000	000	000	N	O
mg	JJ	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
treatment	NN	treatment	treatment	treatment	N	O
arms	NNS	arms	arm	arm	N	O
.	.	.	.	.	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
plus	CC	plus	plus	plu	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
was	VBD	was	wa	wa	N	O
given	VBN	given	given	given	N	O
to	TO	to	to	to	N	O
control	VB	control	control	control	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	VBD	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
abiraterone	NN	abiraterone	abiraterone	abirateron	N	O
acetate	NN	acetate	acetate	acet	N	O
arm	NN	arm	arm	arm	N	O
were	VBD	were	were	were	N	O
fatigue	JJ	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
joint	JJ	joint	joint	joint	N	B-AdverseReaction
swelling	NN	swelling	swelling	swell	Y	I-AdverseReaction
or	CC	or	or	or	N	O
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
edema	NN	edema	edema	edema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hot	JJ	hot	hot	hot	N	B-AdverseReaction
flush	NN	flush	flush	flush	N	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
and	CC	and	and	and	N	O
contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	VBD	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
abiraterone	NN	abiraterone	abiraterone	abirateron	N	O
acetate	NN	acetate	acetate	acet	N	O
arm	NN	arm	arm	arm	N	O
were	VBD	were	were	were	N	O
anemia	RB	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
alkaline	JJ	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
,	,	,	,	,	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypercholesterolemia	NN	hypercholesterolemia	hypercholesterolemia	hypercholesterolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	VBD	elevated	elevated	elev	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
and	CC	and	and	and	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Study	NN	study	study	studi	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Metastatic	JJ	metastatic	metastatic	metastat	N	O
CRPC	NNP	crpc	crpc	crpc	N	O
Following	NNP	following	following	follow	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O

Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
1195	CD	1195	1195	1195	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
CRPC	NNP	crpc	crpc	crpc	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
received	VBN	received	received	receiv	N	O
prior	RB	prior	prior	prior	N	O
docetaxel	JJ	docetaxel	docetaxel	docetaxel	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
eligible	JJ	eligible	eligible	elig	N	O
if	IN	if	if	if	N	O
AST	NNP	ast	ast	ast	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
ALT	NNP	alt	alt	alt	N	O
2.5	CD	2.5	2.5	2.5	N	O
ULN	NNP	uln	uln	uln	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
liver	NN	liver	liver	liver	N	O
metastases	NNS	metastases	metastasis	metastas	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
liver	JJ	liver	liver	liver	N	O
metastases	NNS	metastases	metastasis	metastas	N	O
were	VBD	were	were	were	N	O
excluded	VBN	excluded	excluded	exclud	N	O
if	IN	if	if	if	N	O
AST	NNP	ast	ast	ast	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
ALT	NNP	alt	alt	alt	N	O
5	CD	5	5	5	N	O
ULN	NNP	uln	uln	uln	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
shows	NNS	shows	show	show	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
2%	CD	2%	2%	2%	N	O
absolute	JJ	absolute	absolute	absolut	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
frequency	NN	frequency	frequency	frequenc	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
or	CC	or	or	or	N	O
were	VBD	were	were	were	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
special	JJ	special	special	special	N	O
interest	NN	interest	interest	interest	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
was	VBD	was	wa	wa	N	O
8	CD	8	8	8	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
with	IN	with	with	with	N	O
Prednisone	NNP	prednisone	prednisone	prednison	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
791	CD	791	791	791	N	O
)	)	)	)	)	N	O
Placebo	NN	placebo	placebo	placebo	N	O
with	IN	with	with	with	N	O
Prednisone	NNP	prednisone	prednisone	prednison	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
394	CD	394	394	394	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Adverse	NNP	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4%	CD	4%	4%	4%	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4%	CD	4%	4%	4%	N	O

Musculoskeletal	NN	musculoskeletal	musculoskeletal	musculoskelet	N	O

and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Joint	JJ	joint	joint	joint	N	B-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
29.5	CD	29.5	29.5	29.5	N	O
4.2	CD	4.2	4.2	4.2	N	O
23.4	CD	23.4	23.4	23.4	N	O
4.1	CD	4.1	4.1	4.1	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
26.2	CD	26.2	26.2	26.2	N	O
3.0	CD	3.0	3.0	3.0	N	O
23.1	CD	23.1	23.1	23.1	N	O
2.3	CD	2.3	2.3	2.3	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
26.7	CD	26.7	26.7	26.7	N	O
1.9	CD	1.9	1.9	1.9	N	O
18.3	CD	18.3	18.3	18.3	N	O
0.8	CD	0.8	0.8	0.8	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hot	NNP	hot	hot	hot	N	B-AdverseReaction
flush	VBD	flush	flush	flush	N	I-AdverseReaction
19.0	CD	19.0	19.0	19.0	N	O
0.3	CD	0.3	0.3	0.3	N	O
16.8	CD	16.8	16.8	16.8	N	O
0.3	CD	0.3	0.3	0.3	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
8.5	CD	8.5	8.5	8.5	N	O
1.3	CD	1.3	1.3	1.3	N	O
6.9	CD	6.9	6.9	6.9	N	O
0.3	CD	0.3	0.3	0.3	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
17.6	CD	17.6	17.6	17.6	N	O
0.6	CD	0.6	0.6	0.6	N	O
13.5	CD	13.5	13.5	13.5	N	O
1.3	CD	1.3	1.3	1.3	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
6.1	CD	6.1	6.1	6.1	N	O
0	CD	0	0	0	N	O
3.3	CD	3.3	3.3	3.3	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
11.5	CD	11.5	11.5	11.5	N	O
2.1	CD	2.1	2.1	2.1	N	O
7.1	CD	7.1	7.1	7.1	N	O
0.5	CD	0.5	0.5	0.5	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
5.4	CD	5.4	5.4	5.4	N	O
0	CD	0	0	0	N	O
2.5	CD	2.5	2.5	2.5	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
10.6	CD	10.6	10.6	10.6	N	O
0	CD	0	0	0	N	O
7.6	CD	7.6	7.6	7.6	N	O
0	CD	0	0	0	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
frequency	NN	frequency	frequency	frequenc	N	I-AdverseReaction
7.2	CD	7.2	7.2	7.2	N	O
0.3	CD	0.3	0.3	0.3	N	O
5.1	CD	5.1	5.1	5.1	N	O
0.3	CD	0.3	0.3	0.3	N	O

Nocturia	NNP	nocturia	nocturia	nocturia	Y	B-AdverseReaction
6.2	CD	6.2	6.2	6.2	N	O
0	CD	0	0	0	N	O
4.1	CD	4.1	4.1	4.1	N	O
0	CD	0	0	0	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
poisoning	NN	poisoning	poisoning	poison	Y	O
and	CC	and	and	and	N	O
procedural	JJ	procedural	procedural	procedur	N	O
complications	NNS	complications	complication	complic	N	O

Fractures	NNS	fractures	fracture	fractur	N	B-AdverseReaction
5.9	CD	5.9	5.9	5.9	N	O
1.4	CD	1.4	1.4	1.4	N	O
2.3	CD	2.3	2.3	2.3	N	O
0	CD	0	0	0	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arrhythmia	NNP	arrhythmia	arrhythmia	arrhythmia	Y	B-AdverseReaction
7.2	CD	7.2	7.2	7.2	N	O
1.1	CD	1.1	1.1	1.1	N	O
4.6	CD	4.6	4.6	4.6	N	O
1.0	CD	1.0	1.0	1.0	N	O

Chest	NNP	chest	chest	chest	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
or	CC	or	or	or	N	O
chest	VB	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
3.8	CD	3.8	3.8	3.8	N	O
0.5	CD	0.5	0.5	0.5	N	O
2.8	CD	2.8	2.8	2.8	N	O
0	CD	0	0	0	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
2.3	CD	2.3	2.3	2.3	N	O
1.9	CD	1.9	1.9	1.9	N	O
1.0	CD	1.0	1.0	1.0	N	O
0.3	CD	0.3	0.3	0.3	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
shows	NNS	shows	show	show	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
of	IN	of	of	of	N	O
interest	NN	interest	interest	interest	N	O
from	IN	from	from	from	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
low	JJ	low	low	low	N	B-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
phosphorus	NN	phosphorus	phosphorus	phosphoru	Y	I-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
low	JJ	low	low	low	N	B-AdverseReaction
potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
5%	CD	5%	5%	5%	N	O
rate	NN	rate	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Laboratory	JJ	laboratory	laboratory	laboratori	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
of	IN	of	of	of	N	O
Interest	NNP	interest	interest	interest	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Abiraterone	NNP	abiraterone	abiraterone	abirateron	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
791	CD	791	791	791	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
394	CD	394	394	394	N	O
)	)	)	)	)	N	O

Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormality	NNP	abnormality	abnormality	abnorm	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction

62.5	CD	62.5	62.5	62.5	N	O
0.4	CD	0.4	0.4	0.4	N	O
53.0	CD	53.0	53.0	53.0	N	O
0	CD	0	0	0	N	O

High	JJ	high	high	high	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
30.6	CD	30.6	30.6	30.6	N	O
2.1	CD	2.1	2.1	2.1	N	O
36.3	CD	36.3	36.3	36.3	N	O
1.5	CD	1.5	1.5	1.5	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
28.3	CD	28.3	28.3	28.3	N	O
5.3	CD	5.3	5.3	5.3	N	O
19.8	CD	19.8	19.8	19.8	N	O
1.0	CD	1.0	1.0	1.0	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
23.8	CD	23.8	23.8	23.8	N	O
7.2	CD	7.2	7.2	7.2	N	O
15.7	CD	15.7	15.7	15.7	N	O
5.8	CD	5.8	5.8	5.8	N	O

High	JJ	high	high	high	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
11.1	CD	11.1	11.1	11.1	N	O
1.4	CD	1.4	1.4	1.4	N	O
10.4	CD	10.4	10.4	10.4	N	O
0.8	CD	0.8	0.8	0.8	N	O

High	JJ	high	high	high	N	B-AdverseReaction
Total	NNP	total	total	total	N	I-AdverseReaction
Bilirubin	NNP	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
6.6	CD	6.6	6.6	6.6	N	O
0.1	CD	0.1	0.1	0.1	N	O
4.6	CD	4.6	4.6	4.6	N	O
0	CD	0	0	0	N	O

Study	NN	study	study	studi	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Metastatic	JJ	metastatic	metastatic	metastat	N	O
CRPC	NNP	crpc	crpc	crpc	N	O
Prior	NNP	prior	prior	prior	N	O
to	TO	to	to	to	N	O
Chemotherapy	VB	chemotherapy	chemotherapy	chemotherapi	Y	O

Study	NN	study	study	studi	N	O

2	CD	2	2	2	N	O
enrolled	JJ	enrolled	enrolled	enrol	N	O
1088	CD	1088	1088	1088	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
CRPC	NNP	crpc	crpc	crpc	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
not	RB	not	not	not	N	O
received	VBN	received	received	receiv	N	O
prior	RB	prior	prior	prior	N	O
cytotoxic	JJ	cytotoxic	cytotoxic	cytotox	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
ineligible	JJ	ineligible	ineligible	inelig	N	O
if	IN	if	if	if	N	O
AST	NNP	ast	ast	ast	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
ALT	NNP	alt	alt	alt	N	O
2.5	CD	2.5	2.5	2.5	N	O
ULN	NNP	uln	uln	uln	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
excluded	VBN	excluded	excluded	exclud	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
had	VBD	had	had	had	N	O
liver	NN	liver	liver	liver	N	O
metastases	NNS	metastases	metastasis	metastas	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
shows	NNS	shows	show	show	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
2%	CD	2%	2%	2%	N	O
absolute	JJ	absolute	absolute	absolut	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
frequency	NN	frequency	frequency	frequenc	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
was	VBD	was	wa	wa	N	O
13.8	CD	13.8	13.8	13.8	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
Arm	NNP	arm	arm	arm	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
with	IN	with	with	with	N	O
Prednisone	NNP	prednisone	prednisone	prednison	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
542	CD	542	542	542	N	O
)	)	)	)	)	N	O
Placebo	NN	placebo	placebo	placebo	N	O
with	IN	with	with	with	N	O
Prednisone	NNP	prednisone	prednisone	prednison	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
540	CD	540	540	540	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Adverse	NNP	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4%	CD	4%	4%	4%	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4%	CD	4%	4%	4%	N	O

General	NNP	general	general	gener	N	O

disorders	NNS	disorders	disorder	disord	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
39.1	CD	39.1	39.1	39.1	N	O
2.2	CD	2.2	2.2	2.2	N	O
34.3	CD	34.3	34.3	34.3	N	O
1.7	CD	1.7	1.7	1.7	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
25.1	CD	25.1	25.1	25.1	N	O
0.4	CD	0.4	0.4	0.4	N	O
20.7	CD	20.7	20.7	20.7	N	O
1.1	CD	1.1	1.1	1.1	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
8.7	CD	8.7	8.7	8.7	N	O
0.6	CD	0.6	0.6	0.6	N	O
5.9	CD	5.9	5.9	5.9	N	O
0.2	CD	0.2	0.2	0.2	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Joint	JJ	joint	joint	joint	N	B-AdverseReaction
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
30.3	CD	30.3	30.3	30.3	N	O
2.0	CD	2.0	2.0	2.0	N	O
25.2	CD	25.2	25.2	25.2	N	O
2.0	CD	2.0	2.0	2.0	N	O

Groin	NNP	groin	groin	groin	N	B-AdverseReaction
pain	VBP	pain	pain	pain	Y	I-AdverseReaction
6.6	CD	6.6	6.6	6.6	N	O
0.4	CD	0.4	0.4	0.4	N	O
4.1	CD	4.1	4.1	4.1	N	O
0.7	CD	0.7	0.7	0.7	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
23.1	CD	23.1	23.1	23.1	N	O
0.4	CD	0.4	0.4	0.4	N	O
19.1	CD	19.1	19.1	19.1	N	O
0.6	CD	0.6	0.6	0.6	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
21.6	CD	21.6	21.6	21.6	N	O
0.9	CD	0.9	0.9	0.9	N	O
17.8	CD	17.8	17.8	17.8	N	O
0.9	CD	0.9	0.9	0.9	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
11.1	CD	11.1	11.1	11.1	N	O
0.0	CD	0.0	0.0	0.0	N	O
5.0	CD	5.0	5.0	5.0	N	O
0.2	CD	0.2	0.2	0.2	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hot	NNP	hot	hot	hot	N	B-AdverseReaction
flush	VBD	flush	flush	flush	N	I-AdverseReaction
22.3	CD	22.3	22.3	22.3	N	O
0.2	CD	0.2	0.2	0.2	N	O
18.1	CD	18.1	18.1	18.1	N	O
0.0	CD	0.0	0.0	0.0	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
21.6	CD	21.6	21.6	21.6	N	O
3.9	CD	3.9	3.9	3.9	N	O
13.1	CD	13.1	13.1	13.1	N	O
3.0	CD	3.0	3.0	3.0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
17.3	CD	17.3	17.3	17.3	N	O
0.0	CD	0.0	0.0	0.0	N	O
13.5	CD	13.5	13.5	13.5	N	O
0.2	CD	0.2	0.2	0.2	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
11.8	CD	11.8	11.8	11.8	N	O
2.4	CD	2.4	2.4	2.4	N	O
9.6	CD	9.6	9.6	9.6	N	O
0.9	CD	0.9	0.9	0.9	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
13.5	CD	13.5	13.5	13.5	N	O
0.2	CD	0.2	0.2	0.2	N	O
11.3	CD	11.3	11.3	11.3	N	O
0.0	CD	0.0	0.0	0.0	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
poisoning	NN	poisoning	poisoning	poison	Y	O
and	CC	and	and	and	N	O
procedural	JJ	procedural	procedural	procedur	N	O
complications	NNS	complications	complication	complic	N	O

Contusion	NN	contusion	contusion	contus	Y	B-AdverseReaction
13.3	CD	13.3	13.3	13.3	N	O
0.0	CD	0.0	0.0	0.0	N	O
9.1	CD	9.1	9.1	9.1	N	O
0.0	CD	0.0	0.0	0.0	N	O

Falls	NNP	falls	fall	fall	N	B-AdverseReaction
5.9	CD	5.9	5.9	5.9	N	O
0.0	CD	0.0	0.0	0.0	N	O
3.3	CD	3.3	3.3	3.3	N	O
0.0	CD	0.0	0.0	0.0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
12.7	CD	12.7	12.7	12.7	N	O
0.0	CD	0.0	0.0	0.0	N	O
8.0	CD	8.0	8.0	8.0	N	O
0.0	CD	0.0	0.0	0.0	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
10.7	CD	10.7	10.7	10.7	N	O
0.0	CD	0.0	0.0	0.0	N	O
8.1	CD	8.1	8.1	8.1	N	O
0.0	CD	0.0	0.0	0.0	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hematuria	NNP	hematuria	hematuria	hematuria	Y	B-AdverseReaction
10.3	CD	10.3	10.3	10.3	N	O
1.3	CD	1.3	1.3	1.3	N	O
5.6	CD	5.6	5.6	5.6	N	O
0.6	CD	0.6	0.6	0.6	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
8.1	CD	8.1	8.1	8.1	N	O
0.0	CD	0.0	0.0	0.0	N	O
3.7	CD	3.7	3.7	3.7	N	O
0.0	CD	0.0	0.0	0.0	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
shows	NNS	shows	show	show	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
arm	NN	arm	arm	arm	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
high	JJ	high	high	high	N	B-AdverseReaction
alanine	NN	alanine	alanine	alanin	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5%	CD	5%	5%	5%	N	O
rate	NN	rate	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
Arm	NNP	arm	arm	arm	N	O
of	IN	of	of	of	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

Abiraterone	NNP	abiraterone	abiraterone	abirateron	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
542	CD	542	542	542	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
540	CD	540	540	540	N	O
)	)	)	)	)	N	O

Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormality	NNP	abnormality	abnormality	abnorm	N	O
Grade	NNP	grade	grade	grade	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4%	CD	4%	4%	4%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4%	CD	4%	4%	4%	N	O
Grade	NNP	grade	grade	grade	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4%	CD	4%	4%	4%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4%	CD	4%	4%	4%	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Lymphopenia	NNP	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction

38.2	CD	38.2	38.2	38.2	N	O
8.7	CD	8.7	8.7	8.7	N	O
31.7	CD	31.7	31.7	31.7	N	O
7.4	CD	7.4	7.4	7.4	N	O

Chemistry	NN	chemistry	chemistry	chemistri	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
56.6	CD	56.6	56.6	56.6	N	O
6.5	CD	6.5	6.5	6.5	N	O
50.9	CD	50.9	50.9	50.9	N	O
5.2	CD	5.2	5.2	5.2	N	O

High	JJ	high	high	high	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
41.9	CD	41.9	41.9	41.9	N	O
6.1	CD	6.1	6.1	6.1	N	O
29.1	CD	29.1	29.1	29.1	N	O
0.7	CD	0.7	0.7	0.7	N	O

High	JJ	high	high	high	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
37.3	CD	37.3	37.3	37.3	N	O
3.1	CD	3.1	3.1	3.1	N	O
28.7	CD	28.7	28.7	28.7	N	O
1.1	CD	1.1	1.1	1.1	N	O

Hypernatremia	NNP	hypernatremia	hypernatremia	hypernatremia	Y	B-AdverseReaction
32.8	CD	32.8	32.8	32.8	N	O
0.4	CD	0.4	0.4	0.4	N	O
25.0	CD	25.0	25.0	25.0	N	O
0.2	CD	0.2	0.2	0.2	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
17.2	CD	17.2	17.2	17.2	N	O
2.8	CD	2.8	2.8	2.8	N	O
10.2	CD	10.2	10.2	10.2	N	O
1.7	CD	1.7	1.7	1.7	N	O

Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O

In	IN	in	in	in	N	O

the	DT	the	the	the	N	O
combined	VBN	combined	combined	combin	N	O
data	NNS	data	data	data	N	O
for	IN	for	for	for	N	O
studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
(	(	(	(	(	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
versus	IN	versus	versus	versu	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
and	CC	and	and	and	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
5	CD	5	5	5	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
death	NN	death	death	death	Y	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
arrhythmias	NNS	arrhythmias	arrhythmia	arrhythmia	N	B-AdverseReaction
were	VBD	were	were	were	N	O
grade	JJ	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
or	CC	or	or	or	N	O
2	CD	2	2	2	N	I-Severity
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
one	CD	one	one	one	N	O
death	NN	death	death	death	Y	B-AdverseReaction
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
sudden	JJ	sudden	sudden	sudden	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
arms	NNS	arms	arm	arm	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	B-Negation
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
arms	NNS	arms	arm	arm	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
)	)	)	)	)	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
cardiorespiratory	JJ	cardiorespiratory	cardiorespiratory	cardiorespiratori	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
arms	NNS	arms	arm	arm	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
)	)	)	)	)	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
arms	NNS	arms	arm	arm	N	O
.	.	.	.	.	N	O

Myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
ischemia	NN	ischemia	ischemia	ischemia	Y	I-AdverseReaction
or	CC	or	or	or	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
arms	NNS	arms	arm	arm	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
arms	NNS	arms	arm	arm	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Post	NNP	post	post	post	N	O
Marketing	NNP	marketing	marketing	market	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
additional	JJ	additional	additional	addit	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
non	SYM	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	I-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	I-AdverseReaction
.	.	.	.	.	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
myopathy	NN	myopathy	myopathy	myopathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
rhabdomyolysis	NN	rhabdomyolysis	rhabdomyolysis	rhabdomyolysi	Y	B-AdverseReaction
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Mineralocorticoid	JJ	mineralocorticoid	mineralocorticoid	mineralocorticoid	N	B-AdverseReaction
excess	NN	excess	excess	excess	N	I-AdverseReaction
:	:	:	:	:	N	O
Use	NNP	use	use	use	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
LVEF	NNP	lvef	lvef	lvef	N	O
50%	CD	50%	50%	50%	N	O
or	CC	or	or	or	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
Class	NNP	class	class	class	N	O
III	NNP	iii	iii	iii	N	O
or	CC	or	or	or	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
LVEF	NNP	lvef	lvef	lvef	N	O
50%	CD	50%	50%	50%	N	O
or	CC	or	or	or	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
Class	NNP	class	class	class	N	O
II	NNP	ii	ii	ii	N	O
to	TO	to	to	to	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

Control	NNP	control	control	control	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
and	CC	and	and	and	N	O
correct	JJ	correct	correct	correct	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
before	IN	before	before	befor	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
serum	JJ	serum	serum	serum	N	O
potassium	NN	potassium	potassium	potassium	Y	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
fluid	JJ	fluid	fluid	fluid	N	O
retention	NN	retention	retention	retent	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
monthly	JJ	monthly	monthly	monthli	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Adrenocortical	JJ	adrenocortical	adrenocortical	adrenocort	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
adrenocortical	JJ	adrenocortical	adrenocortical	adrenocort	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	O
dosage	NN	dosage	dosage	dosag	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
indicated	VBN	indicated	indicated	indic	N	O
before	IN	before	before	befor	N	O
,	,	,	,	,	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
stressful	JJ	stressful	stressful	stress	N	O
situations	NNS	situations	situation	situat	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
:	:	:	:	:	N	O
Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
have	VBP	have	have	have	N	O
led	VBN	led	led	led	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
interruption	NN	interruption	interruption	interrupt	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
modification	NN	modification	modification	modif	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
liver	CC	liver	liver	liver	N	O
function	NN	function	function	function	N	O
and	CC	and	and	and	N	O
modify	NN	modify	modify	modifi	N	O
,	,	,	,	,	N	O
interrupt	NN	interrupt	interrupt	interrupt	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
dosing	VBG	dosing	dosing	dose	N	O
as	RB	as	a	as	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	O
,	,	,	,	,	N	O
Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	O
and	CC	and	and	and	N	O
Fluid	NNP	fluid	fluid	fluid	N	O
Retention	NNP	retention	retention	retent	N	O
Due	NNP	due	due	due	N	O
to	TO	to	to	to	N	O
Mineralocorticoid	NNP	mineralocorticoid	mineralocorticoid	mineralocorticoid	N	O
Excess	NNP	excess	excess	excess	N	O

ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fluid	JJ	fluid	fluid	fluid	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
consequence	NN	consequence	consequence	consequ	N	O
of	IN	of	of	of	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
mineralocorticoid	NN	mineralocorticoid	mineralocorticoid	mineralocorticoid	N	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
from	IN	from	from	from	N	O
CYP17	NNP	cyp17	cyp17	cyp17	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
[	NNP	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.1	CD	12.1	12.1	12.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	VBD	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
to	TO	to	to	to	N	I-Severity
4	CD	4	4	4	N	I-Severity
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
to	TO	to	to	to	N	I-Severity
4	CD	4	4	4	N	I-Severity
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
to	TO	to	to	to	N	I-Severity
4	CD	4	4	4	N	I-Severity
edema	NN	edema	edema	edema	Y	B-AdverseReaction
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
[	NNP	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Co	NNP	co	co	co	N	O
-	:	-	-	-	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
corticosteroid	JJ	corticosteroid	corticosteroid	corticosteroid	N	O
suppresses	NNS	suppresses	suppresses	suppress	N	O
adrenocorticotropic	VBP	adrenocorticotropic	adrenocorticotropic	adrenocorticotrop	N	O
hormone	NN	hormone	hormone	hormon	N	O
(	(	(	(	(	N	O
ACTH	NNP	acth	acth	acth	Y	O
)	)	)	)	)	N	O
drive	NN	drive	drive	drive	N	O
,	,	,	,	,	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
reduction	NN	reduction	reduction	reduct	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
treating	VBG	treating	treating	treat	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
underlying	JJ	underlying	underlying	underli	N	O
medical	JJ	medical	medical	medic	N	O
conditions	NNS	conditions	condition	condit	N	O
might	MD	might	might	might	N	O
be	VB	be	be	be	N	O
compromised	VBN	compromised	compromised	compromis	N	O
by	IN	by	by	by	N	O
increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
or	CC	or	or	or	N	O
fluid	NN	fluid	fluid	fluid	N	O
retention	NN	retention	retention	retent	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
recent	JJ	recent	recent	recent	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
or	CC	or	or	or	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
left	JJ	left	left	left	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
ejection	NN	ejection	ejection	eject	N	O
fraction	NN	fraction	fraction	fraction	N	O
50%	CD	50%	50%	50%	N	O
or	CC	or	or	or	N	O
New	NNP	new	new	new	N	O
York	NNP	york	york	york	N	O
Heart	NNP	heart	heart	heart	N	O
Association	NNP	association	association	associ	N	O
(	(	(	(	(	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
)	)	)	)	)	N	O
Class	NNP	class	class	class	N	O
III	NNP	iii	iii	iii	N	O
or	CC	or	or	or	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
(	(	(	(	(	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
Class	NNP	class	class	class	N	O
II	NNP	ii	ii	ii	N	O
to	TO	to	to	to	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
(	(	(	(	(	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
established	VBN	established	established	establish	N	O
because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
excluded	VBN	excluded	excluded	exclud	N	O
from	IN	from	from	from	N	O
these	DT	these	these	these	N	O
randomized	VBN	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fluid	JJ	fluid	fluid	fluid	N	O
retention	NN	retention	retention	retent	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
once	RB	once	once	onc	N	O
a	DT	a	a	a	N	O
month	NN	month	month	month	N	O
.	.	.	.	.	N	O

Control	NNP	control	control	control	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
and	CC	and	and	and	N	O
correct	JJ	correct	correct	correct	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
before	IN	before	before	befor	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Adrenocortical	JJ	adrenocortical	adrenocortical	adrenocort	N	O
Insufficiency	NN	insufficiency	insufficiency	insuffici	N	O

Adrenal	JJ	adrenal	adrenal	adren	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	VBD	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Adrenocortical	JJ	adrenocortical	adrenocortical	adrenocort	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
,	,	,	,	,	N	O
following	VBG	following	following	follow	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
daily	JJ	daily	daily	daili	N	O
steroids	NNS	steroids	steroid	steroid	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
infection	NN	infection	infection	infect	Y	O
or	CC	or	or	or	N	O
stress	NN	stress	stress	stress	Y	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
adrenocortical	JJ	adrenocortical	adrenocortical	adrenocort	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
if	IN	if	if	if	N	O
patients	NNS	patients	patient	patient	N	O
are	VBP	are	are	are	N	O
withdrawn	VBN	withdrawn	withdrawn	withdrawn	Y	O
from	IN	from	from	from	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
prednisone	VBN	prednisone	prednisone	prednison	N	O
dose	JJ	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
experience	VB	experience	experience	experi	N	O
unusual	JJ	unusual	unusual	unusu	N	O
stress	NN	stress	stress	stress	Y	O
.	.	.	.	.	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
adrenocortical	JJ	adrenocortical	adrenocortical	adrenocort	N	B-AdverseReaction
insufficiency	NN	insufficiency	insufficiency	insuffici	N	I-AdverseReaction
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
masked	VBN	masked	masked	mask	N	O
by	IN	by	by	by	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
mineralocorticoid	NN	mineralocorticoid	mineralocorticoid	mineralocorticoid	N	B-AdverseReaction
excess	NN	excess	excess	excess	N	I-AdverseReaction
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
,	,	,	,	,	N	O
perform	VB	perform	perform	perform	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
tests	NNS	tests	test	test	N	O
to	TO	to	to	to	N	O
confirm	VB	confirm	confirm	confirm	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
adrenocortical	JJ	adrenocortical	adrenocortical	adrenocort	N	O
insufficiency	NN	insufficiency	insufficiency	insuffici	N	O
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	O
dosage	NN	dosage	dosage	dosag	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
indicated	VBN	indicated	indicated	indic	N	O
before	IN	before	before	befor	N	O
,	,	,	,	,	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
stressful	JJ	stressful	stressful	stress	N	O
situations	NNS	situations	situation	situat	N	O
[	VBP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	VBD	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
ALT	NNPS	alt	alt	alt	N	B-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
increases	NNS	increases	increase	increas	N	I-AdverseReaction
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
5	CD	5	5	5	N	O
ULN	NNP	uln	uln	uln	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
,	,	,	,	,	N	O
typically	RB	typically	typically	typic	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
baseline	JJ	baseline	baseline	baselin	N	O
ALT	NNP	alt	alt	alt	N	O
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	O
were	VBD	were	were	were	N	O
elevated	VBN	elevated	elevated	elev	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
experience	VB	experience	experience	experi	N	O
liver	RB	liver	liver	liver	N	B-AdverseReaction
test	NN	test	test	test	N	I-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
than	IN	than	than	than	N	O
those	DT	those	those	those	N	O
beginning	VBG	beginning	beginning	begin	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
values	NNS	values	value	valu	N	O
.	.	.	.	.	N	O

Treatment	JJ	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
liver	VB	liver	liver	liver	N	B-AdverseReaction
enzyme	NN	enzyme	enzyme	enzym	N	I-AdverseReaction
increases	NNS	increases	increase	increas	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
deaths	NNS	deaths	death	death	N	B-AdverseReaction
clearly	RB	clearly	clearly	clearli	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hepatotoxicity	JJ	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

Measure	NN	measure	measure	measur	N	O
serum	NN	serum	serum	serum	N	O
transaminases	NNS	transaminases	transaminase	transaminas	Y	O
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	O
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
levels	NNS	levels	level	level	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
two	CD	two	two	two	N	O
weeks	NNS	weeks	week	week	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
three	CD	three	three	three	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
monthly	JJ	monthly	monthly	monthli	N	O
thereafter	NN	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
baseline	JJ	baseline	baseline	baselin	N	O
moderate	JJ	moderate	moderate	moder	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
receiving	VBG	receiving	receiving	receiv	N	O
a	DT	a	a	a	N	O
reduced	VBN	reduced	reduced	reduc	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
250	CD	250	250	250	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
measure	NN	measure	measure	measur	N	O
ALT	NNP	alt	alt	alt	N	O
,	,	,	,	,	N	O
AST	NNP	ast	ast	ast	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
bilirubin	RB	bilirubin	bilirubin	bilirubin	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
week	NN	week	week	week	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
month	NN	month	month	month	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
two	CD	two	two	two	N	O
weeks	NNS	weeks	week	week	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
two	CD	two	two	two	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
monthly	JJ	monthly	monthly	monthli	N	O
thereafter	NN	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

Promptly	RB	promptly	promptly	promptli	N	O
measure	NN	measure	measure	measur	N	O
serum	JJ	serum	serum	serum	N	O
total	JJ	total	total	total	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
,	,	,	,	,	N	O
AST	NNP	ast	ast	ast	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ALT	NNP	alt	alt	alt	N	O
if	IN	if	if	if	N	O
clinical	JJ	clinical	clinical	clinic	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
or	CC	or	or	or	N	O
signs	NNS	signs	sign	sign	N	O
suggestive	CD	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
develop	NN	develop	develop	develop	N	O
.	.	.	.	.	N	O

Elevations	NNS	elevations	elevation	elev	N	O
of	IN	of	of	of	N	O
AST	NNP	ast	ast	ast	N	O
,	,	,	,	,	N	O
ALT	NNP	alt	alt	alt	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
baseline	NN	baseline	baseline	baselin	N	O
should	MD	should	should	should	N	O
prompt	VB	prompt	prompt	prompt	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
time	NN	time	time	time	N	O
AST	NNP	ast	ast	ast	N	O
or	CC	or	or	or	N	O
ALT	NNP	alt	alt	alt	N	O
rise	VBP	rise	rise	rise	N	O
above	RB	above	above	abov	N	O
five	CD	five	five	five	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
ULN	NNP	uln	uln	uln	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
rises	VBZ	rises	rise	rise	N	O
above	IN	above	above	abov	N	O
three	CD	three	three	three	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
ULN	NNP	uln	uln	uln	N	O
,	,	,	,	,	N	O
interrupt	JJ	interrupt	interrupt	interrupt	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
closely	RB	closely	closely	close	N	O
monitor	VB	monitor	monitor	monitor	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Re	NNP	re	re	re	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	JJ	dose	dose	dose	N	O
level	NN	level	level	level	N	O
may	MD	may	may	may	N	O
take	VB	take	take	take	N	O
place	NN	place	place	place	N	O
only	RB	only	only	onli	N	O
after	IN	after	after	after	N	O
return	NN	return	return	return	N	O
of	IN	of	of	of	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
tests	NNS	tests	test	test	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
baseline	NN	baseline	baseline	baselin	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
AST	NNP	ast	ast	ast	N	O
and	CC	and	and	and	N	O
ALT	NNP	alt	alt	alt	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
2.5	CD	2.5	2.5	2.5	N	O
ULN	NNP	uln	uln	uln	N	O
and	CC	and	and	and	N	O
total	JJ	total	total	total	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
1.5	CD	1.5	1.5	1.5	N	O
ULN	NNP	uln	uln	uln	N	O
[	NNP	[	[	[	N	O
seeDosage	NN	seedosage	seedosage	seedosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ZYTIGA	NNP	zytiga	zytiga	zytiga	N	O
re	FW	re	re	re	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
AST	NNP	ast	ast	ast	N	O
or	CC	or	or	or	N	O
ALT	NNP	alt	alt	alt	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
20	CD	20	20	20	N	O
ULN	NNP	uln	uln	uln	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
bilirubin	VB	bilirubin	bilirubin	bilirubin	Y	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
ULN	NNP	uln	uln	uln	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

